Atlas Trials

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Clinical trial NCT05890287 · RECRUITING

Trial details

NCT number
NCT05890287
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
HR Positive HER2 Negative Advanced Breast Cancer
Start date
2023-05-16
Primary completion
2026-05-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.